[go: up one dir, main page]

PT100198A - Nucleosidos terapeuticos - Google Patents

Nucleosidos terapeuticos

Info

Publication number
PT100198A
PT100198A PT100198A PT10019892A PT100198A PT 100198 A PT100198 A PT 100198A PT 100198 A PT100198 A PT 100198A PT 10019892 A PT10019892 A PT 10019892A PT 100198 A PT100198 A PT 100198A
Authority
PT
Portugal
Prior art keywords
therapeutic nucleosides
nucleosides
therapeutic
hepatitis
treatment
Prior art date
Application number
PT100198A
Other languages
English (en)
Other versions
PT100198B (pt
Inventor
George Robert Painter Iii
Phillip Allen Furman Jr
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of PT100198A publication Critical patent/PT100198A/pt
Publication of PT100198B publication Critical patent/PT100198B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT100198A 1991-03-06 1992-03-05 Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos PT100198B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides

Publications (2)

Publication Number Publication Date
PT100198A true PT100198A (pt) 1993-05-31
PT100198B PT100198B (pt) 2000-03-31

Family

ID=26298535

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100198A PT100198B (pt) 1991-03-06 1992-03-05 Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos

Country Status (21)

Country Link
EP (3) EP0574487B1 (pt)
JP (5) JP3479068B2 (pt)
KR (1) KR100270806B1 (pt)
AT (2) ATE361293T1 (pt)
AU (1) AU662130B2 (pt)
CA (1) CA2105486C (pt)
CZ (1) CZ282747B6 (pt)
DE (2) DE69232649T2 (pt)
DK (2) DK0574487T3 (pt)
ES (2) ES2286072T3 (pt)
HU (1) HUT64844A (pt)
IE (1) IE920701A1 (pt)
IL (1) IL101144A (pt)
MX (1) MX9203213A (pt)
NZ (1) NZ264621A (pt)
PT (1) PT100198B (pt)
RU (1) RU2116789C1 (pt)
SK (1) SK279542B6 (pt)
TW (1) TW201268B (pt)
UA (1) UA54364C2 (pt)
WO (1) WO1992015308A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674634T3 (da) * 1989-02-08 2003-08-04 Iaf Biochem Int Fremgangsmåde til fremstilling af substituerede 1,3-oxathiolaner med antivirale egenskaber
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
NZ264621A (en) * 1991-03-06 1997-09-22 Wellcome Found Use of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluoro-cytosine or a physiologically functional derivative thereof in the preparation of medicaments for treatment of hepatitis b
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MXPA01001507A (es) 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
EP1104415B1 (en) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2002257446A1 (en) 2001-05-18 2002-12-03 Rakesh Kumar Antiviral nucleosides
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004024095A2 (en) 2002-09-13 2004-03-25 Idenix (Cayman) Limited ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
BRPI0915284B1 (pt) * 2008-06-30 2020-01-14 Tocagen Inc composição farmacêutica oral, e, uso de uma composição farmacêutica
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196607B (en) * 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
WO1990014079A1 (en) 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
NZ264621A (en) * 1991-03-06 1997-09-22 Wellcome Found Use of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluoro-cytosine or a physiologically functional derivative thereof in the preparation of medicaments for treatment of hepatitis b

Also Published As

Publication number Publication date
DE69233693D1 (de) 2007-06-14
JP2011102308A (ja) 2011-05-26
CA2105486C (en) 2003-10-28
JP2002220388A (ja) 2002-08-09
EP0574487A1 (en) 1993-12-22
UA54364C2 (uk) 2003-03-17
MX9203213A (es) 1992-07-01
IL101144A0 (en) 1992-11-15
HUT64844A (en) 1994-03-28
JP2007246536A (ja) 2007-09-27
RU2116789C1 (ru) 1998-08-10
EP1142891B1 (en) 2007-05-02
CZ183593A3 (en) 1994-04-13
NZ264621A (en) 1997-09-22
JP4399478B2 (ja) 2010-01-13
JP4891435B2 (ja) 2012-03-07
EP1808434A2 (en) 2007-07-18
ES2179040T3 (es) 2003-01-16
EP1142891A1 (en) 2001-10-10
DE69233693T2 (de) 2008-01-24
KR100270806B1 (ko) 2000-11-01
DK1142891T3 (da) 2007-08-27
JP3479068B2 (ja) 2003-12-15
DE69232649D1 (de) 2002-07-25
CZ282747B6 (cs) 1997-09-17
JP2010013466A (ja) 2010-01-21
WO1992015308A1 (en) 1992-09-17
JP3987335B2 (ja) 2007-10-10
DK0574487T3 (da) 2002-10-14
CA2105486A1 (en) 1992-09-07
TW201268B (pt) 1993-03-01
ATE361293T1 (de) 2007-05-15
AU1367692A (en) 1992-10-06
ES2286072T3 (es) 2007-12-01
IE20040402A1 (en) 2007-10-17
AU662130B2 (en) 1995-08-24
ATE219366T1 (de) 2002-07-15
SK95093A3 (en) 1994-04-06
PT100198B (pt) 2000-03-31
IL101144A (en) 1996-09-12
SK279542B6 (sk) 1998-12-02
HU9302493D0 (en) 1993-11-29
IE920701A1 (en) 1992-09-09
JPH06505725A (ja) 1994-06-30
EP0574487B1 (en) 2002-06-19
DE69232649T2 (de) 2002-11-28
EP1808434A3 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
PT100198A (pt) Nucleosidos terapeuticos
EE02995B1 (et) 1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
DK602988A (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
FI862011A0 (fi) Terapeutiska nukleosider.
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
ATE82294T1 (de) Therapeutische nukleoside.
MY137298A (en) Therapeutic nucleosides
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930121

FG3A Patent granted, date of granting

Effective date: 19991210

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20141210